As of December 31, 2022, Immunovant’s cash and cash equivalents totaled $432.6 million, which is expected to fund operations into the second half of calendar year 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMVT:
- Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
- Immunovant participates in a conference call hosted by Truist
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- Immunovant upgraded to Overweight from Equal Weight at Wells Fargo
- Roivant’s upcoming data readouts could move stock higher, says Cantor Fitzgerald